Inovio Pharmaceuticals, Inc. (INO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Inovio Pharmaceuticals, Inc. (INO) Healthcare & Pipeline Overview

Inovio Pharmaceuticals, Inc. pioneers DNA-based medicines, leveraging its SynCon platform and CELLECTRA delivery system to target HPV-associated diseases, cancers, and infectious diseases. With a focus on innovative therapies, Inovio operates within the competitive biotechnology sector, collaborating with various partners to advance its clinical pipeline.

What Is the Investment Thesis for INO?

Inovio Pharmaceuticals presents a high-risk, high-reward investment opportunity. The company's DNA medicine platform, targeting a wide range of diseases from HPV-related cancers to infectious diseases, offers significant potential. However, the company's negative profit margin of -130000.0% and gross margin of -2189.0% highlight substantial financial challenges. Upcoming catalysts include the progression of its clinical trials for various DNA medicines. Success in these trials could drive significant stock appreciation. The company's collaborations with organizations like CEPI and the Bill & Melinda Gates Foundation provide validation and funding. However, potential risks include clinical trial failures, regulatory hurdles, and the need for additional capital. Investors should carefully weigh the potential upside against the significant risks before investing in Inovio.

Based on FMP financials and quantitative analysis

INO Key Highlights

Market capitalization of $83.6M, indicating a small-cap company with potential for growth but also higher volatility.

• Negative profit margin of -130000.0%, reflecting significant losses and highlighting the need for successful product commercialization.
• Negative gross margin of -2189.0%, indicating that the cost of goods sold exceeds revenue, posing a major challenge to profitability.
• Beta of 1.70, suggesting that the stock is more volatile than the overall market.
• No dividend yield, as the company does not currently offer dividends, typical for growth-focused biotechnology companies.

Who Are INO's Competitors?

INO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are INO's Key Strengths?

Proprietary DNA medicine platform.

• CELLECTRA delivery technology.
• Extensive patent portfolio.
• Collaborations with leading institutions.

What Are INO's Weaknesses?

Negative profit and gross margins.

• Dependence on clinical trial success.
• Limited commercialized products.
• High cash burn rate.

What Could Drive INO Stock Higher?

Data readouts from ongoing clinical trials for HPV-associated diseases.

• Progress in the development of DNA vaccines for infectious diseases.
• Expansion of collaborations with strategic partners.
• Advancement of the CELLECTRA delivery technology.

What Are the Key Risks for INO?

Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from other biotechnology companies.
• Need for additional capital to fund operations.
• Intellectual property challenges.

What Are the Growth Opportunities for INO?

• Advancement of HPV-Associated Disease Pipeline: Inovio has a significant opportunity in advancing its DNA medicines targeting HPV-associated diseases, including cervical dysplasia and cancers. The global market for HPV therapeutics is substantial, driven by the high prevalence of HPV infections and the need for effective treatments. Successful completion of clinical trials and regulatory approval could lead to significant revenue generation for Inovio. Timeline: Ongoing clinical trials with potential for data readouts in the next 1-2 years.
• Development of DNA Vaccines for Infectious Diseases: Inovio is developing DNA vaccines for various infectious diseases, including Ebola, MERS, and Lassa fever. The global market for vaccines is growing, driven by increasing awareness of the importance of preventative healthcare and the emergence of new infectious diseases. Inovio's DNA vaccine platform offers the potential for rapid development and deployment of vaccines in response to outbreaks. Timeline: Ongoing research and development efforts with potential for clinical trials in the next 2-3 years.
• Expansion of CELLECTRA Delivery Technology: Inovio's CELLECTRA delivery technology offers a competitive advantage in the delivery of DNA medicines. The company has the opportunity to expand the use of this technology through partnerships and collaborations with other biotechnology and pharmaceutical companies. This could generate revenue through licensing agreements and technology transfer. Timeline: Ongoing efforts to establish partnerships and collaborations.
• Collaboration with Strategic Partners: Inovio's collaborations with organizations like CEPI, the Bill & Melinda Gates Foundation, and AstraZeneca provide access to funding, expertise, and resources. The company can leverage these partnerships to accelerate the development and commercialization of its DNA medicines. Further strategic partnerships could expand Inovio's reach and impact. Timeline: Ongoing collaborations with potential for new partnerships in the future.
• Exploration of DNA Medicines for Cancer Immunotherapy: Inovio is exploring the use of its DNA medicines in cancer immunotherapy. The cancer immunotherapy market is experiencing rapid growth, driven by the success of checkpoint inhibitors and other immunotherapeutic approaches. Inovio's DNA medicines offer the potential to stimulate the immune system to target and destroy cancer cells. Timeline: Ongoing research and development efforts with potential for clinical trials in the next 2-3 years.

What Are INO's Competitive Advantages?

• Proprietary DNA medicine platform with SynCon design and CELLECTRA delivery technology.
• Extensive patent portfolio protecting its technologies and products.
• Established collaborations with leading research institutions and pharmaceutical companies.
• Expertise in DNA medicine development and clinical trial execution.
• Focus on addressing unmet medical needs in HPV-associated diseases, cancer, and infectious diseases.

What Does INO Do?

Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio Pharmaceuticals, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of DNA medicines. The company's core technology revolves around its proprietary DNA medicines platform, which utilizes precisely designed SynCon DNA plasmids to target specific antigens associated with diseases. These SynCon plasmids are optimized to elicit a robust immune response, offering a potential therapeutic or prophylactic effect. A key component of Inovio's platform is the CELLECTRA smart devices technology, which facilitates the efficient delivery of the DNA plasmids into cells. This delivery system enhances the uptake and expression of the DNA, leading to improved immune activation. Inovio's research and development efforts are focused on addressing a range of diseases, including those associated with human papillomavirus (HPV), various cancers, and infectious diseases. The company is actively involved in conducting and planning clinical studies to evaluate the safety and efficacy of its DNA medicines. These studies target HPV-associated precancers, such as cervical, vulvar, and anal dysplasia, as well as HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal cancers. Inovio is also exploring the potential of its DNA medicines to treat other HPV-associated disorders, such as recurrent respiratory papillomatosis. Beyond HPV-related diseases and cancers, Inovio is also investigating the use of its DNA medicines in the treatment of glioblastoma multiforme, prostate cancer, HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company collaborates with a network of partners and collaborators, including ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. These collaborations provide Inovio with access to additional expertise, resources, and funding to support its research and development programs. Inovio also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital.

What Products and Services Does INO Offer?

• Discovers and develops DNA medicines for various diseases.
• Focuses on treating and protecting people from diseases associated with human papillomavirus (HPV).
• Develops DNA medicines for cancer, including glioblastoma multiforme and prostate cancer.
• Creates DNA vaccines for infectious diseases like HIV, Ebola, MERS, and Lassa fever.
• Utilizes SynCon DNA design to optimize DNA sequences for targeted antigens.
• Employs CELLECTRA smart devices technology for efficient DNA plasmid delivery.
• Conducts clinical studies to evaluate the safety and efficacy of its DNA medicines.
• Collaborates with various partners to advance its research and development programs.

How Does INO Make Money?

• Develops and patents DNA medicine technologies.
• Conducts research and clinical trials to validate the efficacy of its products.
• Partners with other companies and organizations for funding and development support.
• Seeks regulatory approval for its DNA medicines.
• Commercializes its approved products through sales and licensing agreements.

What Industry Does INO Operate In?

Inovio Pharmaceuticals operates within the highly competitive biotechnology industry, characterized by rapid innovation and high regulatory hurdles. The industry is driven by the increasing demand for novel therapies to treat a wide range of diseases, including cancer and infectious diseases. Inovio's focus on DNA medicines positions it within a niche segment of the market, competing with companies developing other innovative therapeutic modalities. The biotechnology industry is experiencing significant growth, fueled by advances in genomics, proteomics, and personalized medicine. However, companies in this sector face challenges such as high research and development costs, lengthy clinical trial timelines, and the risk of clinical trial failures.

Who Are INO's Key Customers?

• Patients suffering from HPV-associated diseases and cancers.
• Individuals at risk of contracting infectious diseases.
• Healthcare providers seeking innovative treatment options.
• Government agencies and organizations involved in public health initiatives.
• Pharmaceutical companies interested in licensing or acquiring Inovio's technologies.

Company Profile

Inovio Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Plymouth Meeting, US. The company is led by CEO Jacqueline E. Shea. INO has traded publicly since 1998.

Inovio Pharmaceuticals, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Key Financial Metrics

A current ratio of 1.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.2%, the inverse of the P/E and a quick read on earnings relative to price.

INO Valuation & Market Position

With a $83.6M market cap, Inovio Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, INO's quantitative score of 23/100 is below the peer average of 70/100.

Wall Street analysts project Inovio Pharmaceuticals, Inc. revenue of about $667K for fiscal 2026, with EPS near $-0.76.

INO Financials

INO Latest News

INO Analyst Consensus

INO MoonshotScore

Latest Inovio Pharmaceuticals, Inc. Analysis

INO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources